Evidence map›Paper›PMID 40791911›Full record

ReviewFrontiers in neurology2025

Harnessing artificial intelligence for brain disease: advances in diagnosis, drug discovery, and closed-loop therapeutics.

Su-Jun Fang, Zhao-di Yin, Qi Cai, Li-Fan Li, Peng-Fei Zheng, Li-Zhen Chen

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Su-Jun FangDepartment of Pharmacy, The First Hospital of Putian City, Putian, China.
Zhao-di YinDepartment of Neurology, Peking University People's Hospital, Beijing, China.
Qi CaiSchool of Medicine, Nankai University, Tianjin, China.
Li-Fan LiDepartment of Pharmacy, The First Hospital of Putian City, Putian, China.
Peng-Fei ZhengSchool of Computer Science and Technology, University of Science and Technology of China, Hefei, China.
Li-Zhen ChenDepartment of Pharmacy, The First Hospital of Putian City, Putian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain diseases pose a significant global health challenge due to their complexity and the limitations of traditional medical strategies. Recent advancements in artificial intelligence (AI), especially deep learning models like Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Graph Neural Networks (GNNs), offer powerful new tools for analysis. These neural networks are effective at extracting complex patterns from high-dimensional data. By integrating diverse data sources-such as neuroimaging, multi-omics, and clinical information-multimodal AI provides the comprehensive view needed to understand intricate disease mechanisms. This review outlines how these technologies enhance precision drug development and enable closed-loop treatment systems for brain disorders. Key applications include improving diagnostic accuracy, identifying novel biomarkers, accelerating drug discovery through target identification and virtual screening, and predicting patient-specific treatment responses. These AI-driven methods have the potential to shift medicine from a one-size-fits-all model to a personalized approach, with diagnostics and therapies tailored to individual profiles. However, realizing this potential requires addressing significant challenges related to data access, model interpretability, clinical validation, and practical integration.

Indexed as

artificial intelligencebrainclosed-loop systemdrug discoverypersonalized medicine

Identifiers

PMID40791911
PMCPMC12336123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.